Ginkgo Bioworks Holdings, Inc. (DNA) stock
Close on Nov 12, 2026Market cap $688.89MP/E –Yield –
Ginkgo Bioworks Holdings, Inc. saw revenue fall 13.2% to $130.75M over the twelve months to Sep 30, 2026. Free cash flow was -$173.54M. At the latest close the market valued the company at $688.89M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $688.89M
- P/E ratio
- –
- Price to sales
- 5.27
- Price to book
- 1.75
- Dividend yield
- –
- Free cash flow yield
- -25.19%
Fundamentals
- Revenue
- $130.75M
- Net income
- -$251.03M
- EPS, diluted
- -$4.19
- Free cash flow
- -$173.54M
- Book value per share
- $6.14
- Diluted shares
- 64M
Trading
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Previous close
- $10.25
- Open
- $10.00
- Day's range
- $9.53 – $10.48
- Volume
- 2,498,307
- Average volume (20 days)
- 2,561,616
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 2.75
- 52-week range
- $5.37 – $18.22
- RSI (14 days)
- 47.2
- Volatility (1 year)
- 104.0%
- Relative volume
- 1.41×
- WACC
- 17.4%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | DNA | S&P 500 | Difference | DNA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.2% | -2.7% | −10.5 pts | ||
| 3 months | +41.9% | -1.7% | +43.6 pts | ||
| Year to date | +23.1% | +11.9% | +11.2 pts | ||
| 1 year | +22.4% | +12.0% | +10.4 pts | ||
| 3 years | -80.0% | +78.2% | −158.2 pts | -41.5% | +21.2% |
| 5 years | -98.0% | +73.2% | −171.3 pts | -54.3% | +11.6% |
| 10 years | +2457.5% | +309.6% | +2147.9 pts | +38.3% | +15.1% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ginkgo Bioworks filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Results
- Results
About Ginkgo Bioworks
Biological Products, (No Diagnostic Substances)
Ginkgo Bioworks Holdings, Inc. is a biotechnology company that provides biological research and development services and tools rather than manufacturing end products. It operates through two segments: cell engineering and biosecurity. In cell engineering, Ginkgo offers research services, automated laboratory hardware, computational models, and biological data assets to support the discovery, optimization, and production of biological products. In biosecurity, it provides biomonitoring programs via Canopy and threat surveillance and analytics through Horizon. Ginkgo serves commercial clients in pharmaceuticals, biotechnology, agriculture, and industrial biotech, as well as government agencies.
Company profile, executives and historyGinkgo Bioworks stock: common questions
What is Ginkgo Bioworks's stock price?
DNA closed at $10.23 on Nov 12, 2026, down 0.20% on the day. Over the past 52 weeks it traded between $5.37 and $18.22.
What is Ginkgo Bioworks's market cap?
Ginkgo Bioworks was worth $688.89M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is DNA's P/E ratio?
Ginkgo Bioworks lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.19), so it has no meaningful P/E ratio.
How much revenue does Ginkgo Bioworks make?
Ginkgo Bioworks reported revenue of $130.75M for the twelve months to Sep 30, 2026, down 13.2% from a year earlier.
Does Ginkgo Bioworks pay a dividend?
No. Ginkgo Bioworks has not paid a cash dividend over the last twelve months.
When does Ginkgo Bioworks report earnings next?
Ginkgo Bioworks is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has DNA stock performed over the past year?
Including dividends, DNA returned +22.4% over the past year, against +12.0% for the S&P 500.
Who are Ginkgo Bioworks's competitors?
Companies most similar to Ginkgo Bioworks by business, industry and size include AGEN, BEAM, CGEN, RXRX, RGNX.
See a number that looks wrong?